SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Isis Pharmaceuticals, Inc. Initates Phase 2/3 Study of ISIS-TTR Rx and Earns $7.5 Million Milestone Payment From GlaxoSmithKline